section name header

Pronunciation ⬇

kris-a-BOR-ole

Classifications ⬆ ⬇

Therapeutic Classification: anti-inflammatories

Pharmacologic Classification: phosphodiesterase type 4 inhibitors

Indications ⬆ ⬇

REMS


Action ⬆ ⬇

  • Inhibits phosphodiesterase 4 resulting in ↑ intracellular cyclic adenosine monophosphate levels.
Therapeutic effects:
  • Decreased severity of atopic dermatitis.

Pharmacokinetics ⬆ ⬇

Absorption: Minimal systemic absorption through intact skin.

Distribution: Local distribution after topical administration.

Protein Binding: 97%.

Metabolism/Excretion: Metabolized through liver into inactive metabolites; metabolites excreted in urine.

Half-Life: Unknown.

Time/Action Profile ⬆ ⬇

(improvement in symptoms)

ROUTEONSETPEAKDURATION
Topical8 daysunknownunknown



Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

Derm: burning, stinging

Misc: hypersensitivity reactions

Interactions ⬆ ⬇

Drug-drug:

Route/Dosage ⬆ ⬇

Availability ⬆ ⬇

Assessment ⬆ ⬇

Implementation ⬆ ⬇

Patient/Family Teaching ⬆ ⬇

Evaluation/Desired Outcomes ⬆ ⬇

US Brand Names ⬆

Eucrisa